CELLTRION-HEALTHCARE
19.5.2023 00:02:32 CEST | Business Wire | Press release
Celltrion Healthcare has partnered with a leading patient organisation, the European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), to raise awareness of inflammatory bowel disease (IBD) this World IBD Day (19 May 2023).
The campaign, Where’s CC? (Crohn’s and Colitis), aims to spark conversations about the impact of IBD across people’s lives and how these challenges vary between different age groups.
People are being encouraged to find the hidden CC characters and learn more about the unique challenges they have faced from being diagnosed with IBD to finding a treatment that works for them, at different stages of life, based on real-life patient insights.
Over ten million people worldwide are living with IBD1, a group of conditions including Crohn’s disease and ulcerative colitis (UC). IBD is most commonly diagnosed between the ages of 10 and 401, however it can appear at any point during people’s lives, with 10% to 15% of newly diagnosed cases of IBD being over the age of 60.2
Clinical research, education and understanding however do not reflect this, leaving groups of people feeling left behind and underrepresented. This can impact patient’s ability to benefit from innovative treatment options and high-quality care, impacting their quality of life and disease outcomes.
Visit www.WhereisCC.com to learn more about the campaign and help in shining a light on IBD by finding CC and learning more about their unique experiences.
Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare, said: “Every IBD patient, no matter their age, deserves to feel understood and have access to high quality care and effective, innovative treatments. Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment allows people to have an improved quality of life whilst managing their condition. We are extremely proud to launch the Where’s CC? campaign in collaboration with EFCCA for World IBD Day 2023 to improve understanding of IBD and the challenges that are associated with specific stages of life.
“Through our partnership with EFCCA, we have unparalleled opportunity to turn the tide in IBD and ensure no patient feels alone or left behind in their unique journey.”
Salvo Leone, EFCCA Chairman, commented: “IBD has no age, yet people living with IBD are facing challenges associated with their age that prevent them benefitting from the best treatment options.
“This World IBD Day, we are delighted to have partnered with Celltrion Healthcare to spotlight some of these challenges to raise awareness and improve care for IBD patients across the world. The Where’s CC? campaign includes important patient resources, and we encourage everyone to spread the word as we work towards a situation where all IBD patients can have a good quality of life.”
Molly O’Donoghue, UC patient, said: “Being diagnosed with UC at 15, I thought I would never be able to move away to university or go travelling with my friends. I was on a downward spiral, becoming depressed and isolated, until I found an at-home treatment that gave me a new freedom to do these things as I had always wanted.
“It is so important that people with IBD are not ashamed of their condition, and we talk about the challenges that come with learning to live with the condition at different stages of life. The Where’s CC? campaign is a brilliant way to raise awareness and help people to overcome the challenges that IBD brings.”
- ENDS -
Notes to Editors:
About Inflammatory Bowel Disease (IBD)
IBD is an umbrella term used to describe conditions including Crohn’s disease and UC. Collectively, IBD impacts over ten million people worldwide.1
IBD is a long-term condition and there may be times when the symptoms are severe, known as a flare-up, and times where there are no or few symptoms, known as remission. Symptoms can be debilitating if the condition is not well managed. These often include abdominal pain and cramping, diarrhoea, weight loss and extreme tiredness.3
Treatment for IBD can be transformative in patients’ lives, reducing the impact of the condition on their lives by minimising flare-up of symptoms and maintaining remission. In recent years, the increasing availability of new treatments has transformed IBD patient care. Innovations in treatments, including advances in treatment administration that enable people to access at-home injectable treatment (versus hospital-based treatment), allows people to have an improved quality of life whilst managing their condition.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com
About EFCCA
The European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA) represents 46 national Crohn’s and ulcerative colitis (collectively known as Inflammatory Bowel Disease or IBD) patient associations. We are an organization of people united in our commitment to improve the life of over 10 million people living with IBD worldwide (3.4 million in Europe alone) and to give them a louder voice and more visibility. For more information, please visit: https://efcca.org/
References
1 EFCCA. What is IBD? Available at: https://efcca.org/content/what-ibd [Accessed May 2023]
2 EFCCA. World IBD Day 2023. Available at: https://efcca.org/projects/world-ibd-day-2023 [Accessed May 2023]
3 NHS. Inflammatory bowel disease. Available at: https://www.nhs.uk/conditions/inflammatory-bowel-disease/ [Accessed May 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005512/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom